The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
123
Los Angeles Clinical Site
Los Angeles, California, United States
Mission Hills Clinical Site
Mission Hills, California, United States
Newport Beach Clinical Site
Newport Beach, California, United States
Mean change in diurnal IOP (average of four time points) from baseline
Time frame: 28 days
Evaluating the safety parameters per protocol
Physical and ocular examinations (tolerability, hyperemia, visual acuity, pupillometry, corneal thickness, aqueous cells and flare), vital signs, and safety laboratory evaluations
Time frame: 28 days
Diurnal IOP
Time frame: 28 days
Mean change from baseline in IOP at each measured time point
Time frame: 28 days
Treatment response rates
Time frame: 28 days
Percent change from baseline in IOP at each measured time point
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pasadena Clinical Site
Pasadena, California, United States
Petaluma Clinical Site
Petaluma, California, United States
Morrow Clinical Site
Morrow, Georgia, United States
Roswell Clinical Site
Roswell, Georgia, United States
New York Clinical Site
New York, New York, United States
High Point Clinical Site
High Point, North Carolina, United States
Cranberry Township Clinical Site
Cranberry Township, Pennsylvania, United States
...and 2 more locations